SHP deficiency causes non-responsiveness to antidiabetic effect of TZDs. (A, B) Serum glucose (A) and insulin (B) levels under fasting conditions. 7–8 week-old male ob/ob and ob/ob;Shp
−/− mice were treated with control (open bars) or troglitazone (filled bars) for 2 weeks. (C) Glucose tolerance tests. Intraperitoneal glucose tolerance tests were performed on ob/ob and ob/ob;Shp
−/− mice treated with control (open symbols) or troglitazone (filled symbols) for 2 weeks. n = 4–5 per group. Data are mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 for differences between control and troglitazone-treated ob/ob mice. #P < 0.01 for differences between ob/ob;Shp
−/− (with no effect of troglitazone treatment) and control-treated ob/ob mice.